Journal
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
Volume 16, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13223-020-00472-8
Keywords
Asthma; Anti-inflammatory treatment; Disease control; Patient outcomes
Categories
Funding
- AstraZeneca
Ask authors/readers for more resources
Asthma is a common chronic disease characterized by episodic or persistent respiratory symptoms and airflow limitation. Asthma treatment is based on a stepwise and control-based approach that involves an iterative cycle of assessment, adjustment of the treatment and review of the response aimed to minimize symptom burden and risk of exacerbations. Anti-inflammatory treatment is the mainstay of asthma management. In this review we will discuss the rationale and barriers to the treatment of asthma that may result in poor outcomes. The benefits of currently available treatments and the possible strategies to overcome the barriers that limit the achievement of asthma control in real-life conditions and how these led to the GINA 2019 guidelines for asthma treatment and prevention will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available